| Motif ID |
Motif Logo |
Scanned Score Distribution |
Frequency of Motif |
Replicability Score |
Evolutionary Conservation Score |
Gene Targets |
Gene Ontology of CpGMM targets |
| CG_imr90ipsc_promoter_n_PM_14_38_6 |
 |
 |
1 |
0.2 |
8.23E-05 |
SLC23A1 |
dehydroascorbic acid transport [BP] |
| CG_imr90ipsc_promoter_n_PM_12_312_7 |
 |
 |
3 |
0.6 |
8.39E-05 |
HPSE2,
DDC |
aromatic-L-amino-acid decarboxylase activity [MF],
synaptic vesicle amine transport [BP],
heparanase activity [MF],
phytoalexin metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_117_12 |
 |
 |
3 |
0.6 |
1.80E-04 |
BCL11B,
RANBP3 |
striatal medium spiny neuron differentiation [BP],
intracellular transport [BP],
olfactory bulb axon guidance [BP] |
| CG_imr90ipsc_promoter_n_PM_12_85_8 |
 |
 |
2 |
0.4 |
5.08E-05 |
ACADL |
carnitine catabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_343_11 |
 |
 |
3 |
0.6 |
3.79E-04 |
SUV420H1,
CHST15 |
N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase activity [MF],
histone H4-K20 trimethylation [BP] |
| CG_imr90ipsc_promoter_n_PM_14_14_6 |
 |
 |
5 |
0.8 |
1.19E-04 |
APOBEC1,
MBP,
RHOA,
DAPK2,
PITX2 |
negative regulation of axonogenesis [BP],
response to osmotic stress [BP],
autophagic vacuole lumen [CC],
superior vena cava morphogenesis [BP],
prolactin secreting cell differentiation [BP],
subthalamic nucleus development [BP] |
| CG_imr90ipsc_promoter_n_PM_12_388_7 |
 |
 |
3 |
0.6 |
5.77E-05 |
OGFOD3,
KDM5C,
FZD4 |
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors [MF],
cerebellum vasculature morphogenesis [BP] |
| CG_imr90ipsc_promoter_n_PM_12_410_5 |
 |
 |
2 |
0.4 |
1.09E-04 |
GSR,
MB,
CRYZL1 |
glutathione-disulfide reductase activity [MF],
NADP binding [MF],
slow-twitch skeletal muscle fiber contraction [BP] |
| CG_imr90ipsc_promoter_n_PM_12_370_9 |
 |
 |
2 |
0.4 |
8.65E-05 |
PPIL3,
PPIAL4D,
DCTD |
dCMP deaminase activity [MF],
peptidyl-prolyl cis-trans isomerase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_6_17 |
 |
 |
2 |
0.4 |
5.58E-06 |
SLC38A7 |
L-asparagine transmembrane transporter activity [MF],
L-leucine transmembrane transporter activity [MF],
L-methionine transmembrane transporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_188_9 |
 |
 |
3 |
0.6 |
2.81E-04 |
PSMD5 |
protein binding involved in protein folding [MF],
proteasome regulatory particle, base subcomplex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_45_15 |
 |
 |
2 |
0.4 |
3.53E-05 |
PRKCQ,
GCLC,
TXNDC12,
TAB3 |
protein-disulfide reductase (glutathione) activity [MF],
cell redox homeostasis [BP],
positive regulation of T-helper 2 cell activation [BP],
glutamate-cysteine ligase activity [MF],
positive regulation of NF-kappaB transcription factor activity [BP] |
| CG_imr90ipsc_promoter_n_PM_12_307_10 |
 |
 |
1 |
0.2 |
1.73E-04 |
FTCD |
formimidoyltetrahydrofolate cyclodeaminase activity [MF],
glutamate formimidoyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_177_11 |
 |
 |
2 |
0.4 |
1.26E-04 |
QARS,
SDF4 |
zymogen granule exocytosis [BP],
glutaminyl-tRNA aminoacylation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_228_5 |
 |
 |
2 |
0.4 |
2.55E-04 |
UBA3 |
NEDD8 activating enzyme activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_168_11 |
 |
 |
3 |
0.4 |
1.26E-04 |
MFSD10 |
tetracycline transport [BP],
tetracycline transporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_412_6 |
 |
 |
2 |
0.4 |
4.51E-05 |
BCOR |
negative regulation of tooth mineralization [BP],
negative regulation of histone H3-K36 methylation [BP],
negative regulation of histone H3-K4 methylation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_303_11 |
 |
 |
2 |
0.4 |
1.08E-04 |
A4GALT |
lactosylceramide 4-alpha-galactosyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_97_10 |
 |
 |
2 |
0.4 |
4.53E-05 |
PCSK6,
PDGFA |
eukaryotic cell surface binding [MF] |
| CG_imr90ipsc_promoter_n_PM_14_29_12 |
 |
 |
3 |
0.6 |
6.23E-05 |
EEF1A1,
EEF1A2,
NMT2,
NDUFAB1 |
eukaryotic translation elongation factor 1 complex [CC],
protein lipoylation [BP],
translation elongation factor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_224_8 |
 |
 |
2 |
0.4 |
2.00E-04 |
ROR2,
COL2A1 |
collagen type II [CC],
cartilage condensation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_169_12 |
 |
 |
3 |
0.4 |
1.44E-04 |
EEA1 |
synaptic vesicle to endosome fusion [BP],
serine-pyruvate aminotransferase complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_142_16 |
 |
 |
3 |
0.6 |
1.50E-04 |
NTRK3,
TENM1,
FOXA2,
CRMP1,
QARS,
GAS6,
OPHN1 |
modulation by virus of host transcription [BP],
positive regulation of axon extension involved in regeneration [BP],
positive regulation of peptidyl-serine phosphorylation [BP],
activation of protein kinase B activity [BP],
regulation of transcription from RNA polymerase III promoter [BP],
peptidyl-serine phosphorylation [BP],
regulation of transcription from RNA polymerase II promoter involved in detection of glucose [BP],
cellular response to vitamin K [BP],
neuron fate specification [BP],
negative regulation of renal albumin absorption [BP],
negative regulation of detection of glucose [BP],
negative regulation of transcription from RNA polymerase II promoter by glucose [BP],
glutamine-tRNA ligase activity [MF],
glutaminyl-tRNA aminoacylation [BP],
negative regulation of oligodendrocyte apoptotic process [BP],
nervous system development [BP] |
| CG_imr90ipsc_promoter_n_PM_12_4_15 |
 |
 |
5 |
0.8 |
7.04E-05 |
C22orf28,
BRD7,
RCHY1 |
RNA ligase (ATP) activity [MF],
p53 binding [MF] |
| CG_imr90ipsc_promoter_n_PM_16_21_9 |
 |
 |
1 |
0.2 |
8.10E-05 |
NRL |
positive regulation of rhodopsin gene expression [BP] |
| CG_imr90ipsc_promoter_n_PM_12_318_14 |
 |
 |
2 |
0.4 |
2.36E-04 |
SDF4 |
zymogen granule exocytosis [BP] |
| CG_imr90ipsc_promoter_n_PM_12_328_14 |
 |
 |
3 |
0.6 |
3.53E-04 |
SLC1A6 |
L-aspartate transmembrane transporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_250_19 |
 |
 |
3 |
0.6 |
1.88E-05 |
UNC13D,
CLPX |
mitochondrial endopeptidase Clp complex [CC],
granuloma formation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_197_13 |
 |
 |
3 |
0.6 |
1.00E-04 |
B3GALNT1,
FOXA2 |
negative regulation of detection of glucose [BP],
negative regulation of transcription from RNA polymerase II promoter by glucose [BP],
regulation of transcription from RNA polymerase II promoter involved in detection of glucose [BP],
negative regulation of glucokinase activity [BP],
galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_195_12 |
 |
 |
2 |
0.4 |
2.18E-04 |
HRC,
CAMK2G |
sarcoplasmic reticulum membrane [CC] |
| CG_imr90ipsc_promoter_n_PM_12_140_14 |
 |
 |
2 |
0.4 |
9.72E-05 |
TBX20 |
pulmonary valve formation [BP],
foramen ovale closure [BP],
pulmonary vein morphogenesis [BP],
embryonic heart tube elongation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_166_8 |
 |
 |
1 |
0.2 |
1.65E-04 |
MC2R,
CYP1A1 |
flavonoid 3'-monooxygenase activity [MF],
corticotropin receptor activity [MF],
dibenzo-p-dioxin catabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_59_9 |
 |
 |
2 |
0.4 |
6.26E-05 |
MBOAT4,
NACC2 |
negative regulation of G1/S transition of mitotic cell cycle by negative regulation of transcription from RNA polymerase II promoter [BP],
peptidyl-serine octanoylation [BP],
serine O-acyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_10_7 |
 |
 |
2 |
0.4 |
2.93E-05 |
GPC3,
JAK3,
LCP1,
PHOX2B,
PHYH,
COG4 |
peptidyl-dipeptidase inhibitor activity [MF],
Golgi vesicle prefusion complex stabilization [BP],
efferent axon development in a lateral line nerve [BP],
phytanoyl-CoA dioxygenase activity [MF],
medullary reticular formation development [BP],
T cell activation involved in immune response [BP],
neural crest cell migration involved in autonomic nervous system development [BP],
negative regulation of FasL biosynthetic process [BP],
retrotrapezoid nucleus neuron differentiation [BP] |
| CG_imr90ipsc_promoter_n_PM_16_11_13 |
 |
 |
1 |
0.2 |
3.08E-05 |
CITED1 |
response to interleukin-11 [BP] |
| CG_imr90ipsc_promoter_n_PM_12_57_9 |
 |
 |
3 |
0.6 |
8.76E-05 |
YBX2 |
oocyte development [BP],
translational attenuation [BP] |
| CG_imr90ipsc_promoter_n_PM_14_53_9 |
 |
 |
1 |
0.2 |
1.51E-04 |
AGXT2,
GNRH1 |
(R)-3-amino-2-methylpropionate-pyruvate transaminase activity [MF],
L-alanine catabolic process, by transamination [BP],
gonadotropin hormone-releasing hormone activity [MF],
beta-alanine-pyruvate transaminase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_182_18 |
 |
 |
3 |
0.6 |
5.89E-05 |
C3AR1,
TACR2,
UROC1,
SLC6A3 |
C3a anaphylatoxin receptor activity [MF],
complement component C3a receptor activity [MF],
prolactin secretion [BP],
urocanate hydratase activity [MF],
dopamine:sodium symporter activity [MF],
substance K receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_74_7 |
 |
 |
1 |
0.2 |
4.48E-05 |
PPP1R9B |
cellular response to morphine [BP] |
| CG_imr90ipsc_promoter_n_PM_14_18_6 |
 |
 |
3 |
0.6 |
6.17E-05 |
PTRF,
PIK3IP1,
AGMAT,
B4GALT1 |
agmatinase activity [MF],
rRNA primary transcript binding [MF],
phosphatidylinositol 3-kinase catalytic subunit binding [MF],
negative regulation of phosphatidylinositol 3-kinase activity [BP],
putrescine biosynthetic process from arginine [BP],
glycocalyx [CC] |
| CG_imr90ipsc_promoter_n_PM_12_37_12 |
 |
 |
2 |
0.4 |
4.21E-05 |
SLC4A7 |
cochlear nucleus development [BP] |
| CG_imr90ipsc_promoter_n_PM_12_30_8 |
 |
 |
3 |
0.6 |
6.95E-05 |
TOLLIP |
interleukin-18 receptor complex [CC],
interleukin-1, Type I receptor binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_210_12 |
 |
 |
4 |
0.8 |
8.33E-06 |
TTPA,
RGS11,
MGLL |
regulation of G-protein coupled receptor protein signaling pathway [BP],
negative regulation of establishment of blood-brain barrier [BP],
regulation of endocannabinoid signaling pathway [BP] |
| CG_imr90ipsc_promoter_n_PM_12_202_9 |
 |
 |
2 |
0.4 |
6.21E-05 |
CDO1 |
cysteine dioxygenase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_26_43 |
 |
 |
6 |
1.0 |
6.38E-05 |
HRAS,
DROSHA,
SPIRE1,
DICER1,
MYH9 |
miRNA metabolic process [BP],
ribonuclease III activity [MF],
positive regulation of miRNA metabolic process [BP],
establishment of meiotic spindle localization [BP] |
| CG_imr90ipsc_promoter_n_PM_16_44_15 |
 |
 |
2 |
0.4 |
2.43E-05 |
CRLF1 |
CRLF-CLCF1 complex [CC],
negative regulation of motor neuron apoptotic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_200_8 |
 |
 |
2 |
0.4 |
1.13E-04 |
GPLD1,
MAD1L1 |
GPI anchor release [BP],
mitotic telophase [BP],
cellular response to triglyceride [BP],
glycosylphosphatidylinositol phospholipase D activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_116_14 |
 |
 |
4 |
0.8 |
3.70E-05 |
SPINT3,
ACVR1C,
VN1R4,
CH25H,
SERPINA12 |
nodal binding [MF],
negative regulation of chorionic trophoblast cell proliferation [BP],
response to pheromone [BP],
negative regulation of trophoblast cell migration [BP],
activin receptor complex [CC],
cholesterol 25-hydroxylase activity [MF],
serine-type endopeptidase inhibitor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_119_8 |
 |
 |
1 |
0.2 |
1.75E-04 |
CDIPT |
CDP-diacylglycerol-inositol 3-phosphatidyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_102_11 |
 |
 |
1 |
0.2 |
1.27E-05 |
KNCN,
COL6A3,
ERV3-1 |
viral envelope [CC],
collagen type VI [CC],
kinocilium [CC] |
| CG_imr90ipsc_promoter_n_PM_16_40_16 |
 |
 |
4 |
0.8 |
6.00E-05 |
MAP4K3,
CHD5,
DDX39A,
DCXR,
CPEB1,
ATP8B3,
MYO1C,
SEPHS2,
KIFC3,
YWHAE,
MST1R |
kinesin complex [CC],
ATP binding [MF],
nucleotide binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_148_24 |
 |
 |
3 |
0.6 |
9.59E-05 |
ACD,
TNKS1BP1 |
telomere maintenance via telomerase [BP],
positive regulation of single-stranded telomeric DNA binding [BP],
chromosome, telomeric region [CC] |
| CG_imr90ipsc_promoter_n_PM_16_42_17 |
 |
 |
7 |
1.0 |
3.22E-05 |
SYNJ1,
IP6K2,
IPO8,
RANBP9 |
phosphatidylinositol phosphorylation [BP],
Ran GTPase binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_98_17 |
 |
 |
3 |
0.6 |
1.78E-04 |
CENPJ |
gamma-tubulin small complex [CC] |
| CG_imr90ipsc_promoter_n_PM_14_100_10 |
 |
 |
2 |
0.4 |
5.85E-05 |
PAK1,
MYO1F |
filamentous actin [CC] |
| CG_imr90ipsc_promoter_n_PM_12_380_6 |
 |
 |
4 |
0.8 |
1.39E-04 |
SLX4,
BDH2 |
Slx1-Slx4 complex [CC],
ERCC4-ERCC1 complex [CC],
3-hydroxybutyrate dehydrogenase activity [MF],
Holliday junction resolvase complex [CC],
siderophore biosynthetic process [BP],
3'-flap endonuclease activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_71_9 |
 |
 |
1 |
0.2 |
1.13E-04 |
PREX1,
NCF2 |
superoxide metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_73_8 |
 |
 |
1 |
0.2 |
2.48E-05 |
SLC16A8 |
lactate transmembrane transport [BP],
lactate transmembrane transporter activity [MF],
lactate transport [BP] |
| CG_imr90ipsc_promoter_n_PM_12_58_9 |
 |
 |
2 |
0.4 |
5.43E-05 |
NOX3,
NKX2-1,
CD74 |
NOS2-CD74 complex [CC],
macrophage migration inhibitory factor signaling pathway [BP],
globus pallidus development [BP],
menarche [BP],
detection of gravity [BP],
macrophage migration inhibitory factor binding [MF],
macrophage migration inhibitory factor receptor complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_376_10 |
 |
 |
1 |
0.2 |
1.48E-04 |
GALNS |
N-acetylgalactosamine-4-sulfatase activity [MF],
N-acetylgalactosamine-6-sulfatase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_89_12 |
 |
 |
2 |
0.4 |
6.43E-05 |
VPS54,
STX10 |
retrograde transport, endosome to Golgi [BP] |
| CG_imr90ipsc_promoter_n_PM_12_386_7 |
 |
 |
1 |
0.2 |
2.51E-04 |
PRKACA,
PDGFB |
negative regulation of phosphatidylinositol biosynthetic process [BP],
positive regulation of hyaluronan biosynthetic process [BP],
paracrine signaling [BP],
metanephric glomerular endothelium development [BP],
metanephric glomerular mesangial cell development [BP],
peptidyl-serine phosphorylation [BP],
positive regulation of glomerular filtration [BP],
fibroblast growth factor receptor signaling pathway [BP],
protein autophosphorylation [BP],
positive regulation of metanephric mesenchymal cell migration [BP],
cellular response to mycophenolic acid [BP],
positive regulation of glomerular mesangial cell proliferation [BP],
positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway [BP] |
| CG_imr90ipsc_promoter_n_PM_12_268_9 |
 |
 |
1 |
0.2 |
1.28E-05 |
PIF1 |
ATP-dependent 5'-3' DNA helicase activity [MF],
single-stranded DNA-dependent ATP-dependent DNA helicase activity [MF],
ATP-dependent 5'-3' DNA/RNA helicase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_36_7 |
 |
 |
1 |
0.2 |
6.60E-05 |
SLC15A1 |
proton-dependent oligopeptide secondary active transmembrane transporter activity [MF],
peptide:hydrogen symporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_347_7 |
 |
 |
2 |
0.4 |
9.20E-05 |
KISS1 |
kisspeptin receptor binding [MF],
positive regulation of luteinizing hormone secretion [BP],
generation of ovulation cycle rhythm [BP] |
| CG_imr90ipsc_promoter_n_PM_12_399_15 |
 |
 |
3 |
0.6 |
1.39E-04 |
AQP3 |
regulation of keratinocyte differentiation [BP] |
| CG_imr90ipsc_promoter_n_PM_14_39_9 |
 |
 |
4 |
0.8 |
5.31E-05 |
ASNS |
L-asparagine biosynthetic process [BP] |
| CG_imr90ipsc_promoter_n_PM_14_17_7 |
 |
 |
1 |
0.2 |
7.31E-05 |
SMAD2,
PITX2 |
left lung morphogenesis [BP],
pulmonary vein morphogenesis [BP],
positive regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry [BP],
superior vena cava morphogenesis [BP],
activating transcription factor binding [MF],
determination of left/right symmetry [BP],
prolactin secreting cell differentiation [BP],
subthalamic nucleus development [BP],
transcription factor complex [CC],
hypothalamus cell migration [BP] |
| CG_imr90ipsc_promoter_n_PM_12_404_15 |
 |
 |
2 |
0.4 |
1.25E-04 |
CCNT1 |
snRNA binding [MF] |
| CG_imr90ipsc_promoter_n_PM_16_4_13 |
 |
 |
1 |
0.2 |
3.10E-05 |
LONP1,
LSS,
EIF2AK1 |
mitochondrial heavy strand promoter anti-sense binding [MF],
oxidation-dependent protein catabolic process [BP],
lanosterol synthase activity [MF],
negative regulation of translational initiation by iron [BP],
DNA polymerase binding [MF],
mitochondrial light strand promoter anti-sense binding [MF],
regulation of eIF2 alpha phosphorylation by heme [BP],
negative regulation of hemoglobin biosynthetic process [BP] |
| CG_imr90ipsc_promoter_n_PM_14_64_12 |
 |
 |
2 |
0.4 |
6.37E-05 |
MAD2L2 |
zeta DNA polymerase complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_189_6 |
 |
 |
2 |
0.4 |
1.47E-05 |
NGLY1,
IP6K3 |
peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase activity [MF],
inositol hexakisphosphate 6-kinase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_16_19_50 |
 |
 |
5 |
1.0 |
6.95E-05 |
RHOA |
negative regulation of axonogenesis [BP] |
| CG_imr90ipsc_promoter_n_PM_12_164_18 |
 |
 |
3 |
0.6 |
9.71E-05 |
ACD,
DBN1 |
cell communication by chemical coupling [BP],
positive regulation of single-stranded telomeric DNA binding [BP],
actomyosin [CC] |
| CG_imr90ipsc_promoter_n_PM_12_221_12 |
 |
 |
3 |
0.4 |
7.57E-05 |
RASGRF1,
EPHA2 |
activation of Rac GTPase activity [BP] |
| CG_imr90ipsc_promoter_n_PM_12_92_16 |
 |
 |
2 |
0.4 |
6.04E-05 |
PAXIP1,
UTS2 |
positive regulation of circadian sleep/wake cycle, REM sleep [BP],
positive regulation of circadian sleep/wake cycle, wakefulness [BP],
positive regulation of histone H3-K36 methylation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_363_7 |
 |
 |
4 |
0.8 |
8.56E-05 |
LPCAT1,
MICALL2 |
negative regulation of phosphatidylcholine biosynthetic process [BP],
actin filament bundle [CC] |
| CG_imr90ipsc_promoter_n_PM_12_389_8 |
 |
 |
2 |
0.4 |
7.94E-05 |
MTHFR |
methylenetetrahydrofolate reductase (NADPH) activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_260_6 |
 |
 |
1 |
0.2 |
1.15E-04 |
FOXP3 |
positive regulation of peripheral T cell tolerance induction [BP] |
| CG_imr90ipsc_promoter_n_PM_12_27_15 |
 |
 |
2 |
0.4 |
9.68E-05 |
MGAT4B |
alpha-1,3-mannosylglycoprotein 4-beta-N-acetylglucosaminyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_162_18 |
 |
 |
1 |
0.2 |
1.02E-04 |
TSC1,
NACC2 |
rRNA export from nucleus [BP],
negative regulation of G1/S transition of mitotic cell cycle by negative regulation of transcription from RNA polymerase II promoter [BP] |
| CG_imr90ipsc_promoter_n_PM_12_111_18 |
 |
 |
2 |
0.4 |
8.45E-05 |
CYP17A1,
NUP160,
NDUFA10,
ACTC1,
HACL1 |
glucose transport [BP],
regulation of glucose transport [BP],
response to acetate [BP],
response to drug [BP],
steroid 17-alpha-monooxygenase activity [MF],
actomyosin, actin part [CC],
hexose transport [BP],
small molecule metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_50_13 |
 |
 |
2 |
0.4 |
4.04E-04 |
PRC1,
DCXR |
mitotic spindle elongation [BP],
L-xylulose reductase (NADP+) activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_232_10 |
 |
 |
2 |
0.4 |
4.25E-05 |
ASB3,
MYO1C,
FUCA1,
TCEB2,
RCHY1 |
protein ubiquitination [BP],
positive regulation of vascular endothelial growth factor signaling pathway [BP],
ubiquitin ligase complex [CC],
stereocilium membrane [CC],
alpha-L-fucosidase activity [MF],
myosin I complex [CC] |
| CG_imr90ipsc_promoter_n_PM_16_24_12 |
 |
 |
1 |
0.2 |
5.60E-05 |
MAN2B1 |
protein deglycosylation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_418_10 |
 |
 |
2 |
0.4 |
2.89E-05 |
SRPK2,
MAP4K1 |
nuclear speck organization [BP],
MAP kinase kinase kinase kinase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_369_6 |
 |
 |
1 |
0.2 |
2.61E-04 |
SLC13A3 |
high affinity sodium:dicarboxylate symporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_411_10 |
 |
 |
2 |
0.4 |
2.58E-04 |
HNRNPD,
PCBP4 |
ribonucleoprotein complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_52_12 |
 |
 |
3 |
0.4 |
7.27E-05 |
PLEC,
SPTB |
ankyrin binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_29_8 |
 |
 |
3 |
0.6 |
9.45E-05 |
GPM6B,
PFN1 |
actin cytoskeleton organization [BP],
regulation of actin cytoskeleton organization [BP] |
| CG_imr90ipsc_promoter_n_PM_12_265_11 |
 |
 |
2 |
0.2 |
2.17E-04 |
ERCC2,
F3,
CYP11A1,
MYH7,
PXN |
cholesterol monooxygenase (side-chain-cleaving) activity [MF],
BH4 domain binding [MF],
positive regulation of platelet-derived growth factor receptor signaling pathway [BP],
response to oxidative stress [BP],
activation of blood coagulation via clotting cascade [BP],
ATPase activity [MF],
response to genistein [BP] |
| CG_imr90ipsc_promoter_n_PM_14_11_4 |
 |
 |
2 |
0.4 |
8.32E-05 |
MTFMT,
PLXNA2 |
cerebellar granule cell precursor tangential migration [BP],
methionyl-tRNA formyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_54_7 |
 |
 |
3 |
0.6 |
8.46E-05 |
SCN10A,
SNAP91,
INSR,
CYBA,
INSRR,
BAIAP2L2 |
phosphatidylinositol 3-kinase binding [MF],
protein tyrosine kinase activity [MF],
insulin receptor substrate binding [MF],
clathrin coat [CC],
male sex determination [BP],
respiratory burst [BP],
clathrin complex [CC],
transmembrane receptor protein tyrosine kinase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_409_11 |
 |
 |
2 |
0.4 |
4.70E-05 |
PPA1,
OCSTAMP |
positive regulation of osteoclast proliferation [BP],
multinuclear osteoclast differentiation [BP],
diphosphate metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_11_13 |
 |
 |
5 |
0.6 |
5.83E-05 |
STOML2,
HSPD1 |
positive regulation of T cell mediated immune response to tumor cell [BP],
cardiolipin binding [MF],
positive regulation of mitochondrial DNA replication [BP],
positive regulation of cardiolipin metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_320_13 |
 |
 |
2 |
0.4 |
2.60E-04 |
LEPREL1,
FUT6 |
3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity [MF],
procollagen-proline 3-dioxygenase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_201_8 |
 |
 |
3 |
0.6 |
1.55E-04 |
OXER1 |
5-hydroxy-6E,8Z,11Z,14Z-icosatetraenoic acid binding [MF],
5(S)-hydroxyperoxy-6E,8Z,11Z,14Z-icosatetraenoic acid binding [MF],
5-oxo-6E,8Z,11Z,14Z-icosatetraenoic acid binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_259_5 |
 |
 |
1 |
0.2 |
1.55E-05 |
BNC1,
ENG,
ZNF318,
EEF1G,
NUPR1,
ATF6B,
SOX18 |
regulation of cell proliferation [BP],
regulation of transcription, DNA-dependent [BP],
heart looping [BP],
transcription, DNA-dependent [BP],
embryonic heart tube development [BP],
gene expression [BP],
establishment of endothelial barrier [BP] |
| CG_imr90ipsc_promoter_n_PM_12_336_7 |
 |
 |
3 |
0.6 |
8.71E-05 |
TMED10,
ICA1 |
secretory granule membrane [CC] |
| CG_imr90ipsc_promoter_n_PM_12_296_7 |
 |
 |
4 |
0.8 |
1.67E-04 |
SLC13A4,
SLC26A1 |
sulfate transmembrane transporter activity [MF],
sulfate transport [BP],
secondary active sulfate transmembrane transporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_183_20 |
 |
 |
2 |
0.4 |
8.54E-05 |
CLDN6,
CLDN22 |
calcium-independent cell-cell adhesion [BP] |
| CG_imr90ipsc_promoter_n_PM_12_253_8 |
 |
 |
2 |
0.4 |
3.48E-05 |
SLC2A2,
L2HGDH |
2-hydroxyglutarate dehydrogenase activity [MF],
hexose transmembrane transport [BP] |
| CG_imr90ipsc_promoter_n_PM_12_405_7 |
 |
 |
2 |
0.2 |
2.50E-05 |
BAK1 |
BH domain binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_298_8 |
 |
 |
2 |
0.4 |
2.00E-05 |
PHKG1,
SERPINC1,
ITGB1 |
protease binding [MF],
enzyme binding [MF],
alpha3-beta1 integrin complex [CC],
alpha9-beta1 integrin complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_160_19 |
 |
 |
3 |
0.6 |
9.98E-05 |
SCARA5,
HEYL |
AF-1 domain binding [MF],
ferritin receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_309_9 |
 |
 |
2 |
0.4 |
7.42E-05 |
CLN3,
FKBP8 |
integral to endoplasmic reticulum membrane [CC] |
| CG_imr90ipsc_promoter_n_PM_12_90_9 |
 |
 |
2 |
0.4 |
1.06E-04 |
CYP2A6 |
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen [MF],
coumarin 7-hydroxylase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_294_9 |
 |
 |
2 |
0.4 |
1.43E-04 |
CLIP1 |
macropinosome [CC] |
| CG_imr90ipsc_promoter_n_PM_16_39_15 |
 |
 |
5 |
1.0 |
3.59E-05 |
JAK3,
SLC11A2 |
vanadium ion transmembrane transporter activity [MF],
paraferritin complex [CC],
nickel cation transport [BP],
cadmium ion transmembrane transporter activity [MF],
ferrous iron import [BP],
lead ion transport [BP],
ferrous iron transport [BP],
nickel cation transmembrane transport [BP],
lead ion transmembrane transporter activity [MF],
negative regulation of FasL biosynthetic process [BP],
vanadium ion transport [BP] |
| CG_imr90ipsc_promoter_n_PM_16_1_6 |
 |
 |
6 |
1.0 |
2.31E-05 |
MYL2,
PCYT1A |
choline-phosphate cytidylyltransferase activity [MF],
muscle cell fate specification [BP] |
| CG_imr90ipsc_promoter_n_PM_12_205_6 |
 |
 |
2 |
0.4 |
5.35E-05 |
DBN1,
ANKH,
PLTP,
OCA2,
SLC6A3 |
vitamin E biosynthetic process [BP],
L-tyrosine transmembrane transporter activity [MF],
dopamine:sodium symporter activity [MF],
inorganic diphosphate transmembrane transporter activity [MF],
arsenite transport [BP],
cell communication by chemical coupling [BP],
tyrosine transport [BP] |
| CG_imr90ipsc_promoter_n_PM_12_226_18 |
 |
 |
3 |
0.6 |
2.64E-04 |
TUSC2,
DDO |
interleukin-15 production [BP],
D-amino-acid oxidase activity [MF],
D-aspartate oxidase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_84_11 |
 |
 |
2 |
0.4 |
6.12E-05 |
COL7A1,
SNRPD2 |
collagen type VII [CC],
spliceosomal complex assembly [BP] |
| CG_imr90ipsc_promoter_n_PM_12_333_13 |
 |
 |
2 |
0.4 |
2.46E-05 |
LYPLA1 |
palmitoyl-(protein) hydrolase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_89_8 |
 |
 |
1 |
0.2 |
5.93E-05 |
STX2,
STX19 |
SNAP receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_267_14 |
 |
 |
3 |
0.6 |
5.74E-05 |
TSC1 |
rRNA export from nucleus [BP] |
| CG_imr90ipsc_promoter_n_PM_12_70_7 |
 |
 |
2 |
0.4 |
2.35E-05 |
DIAPH1,
CD59 |
cellular response to histamine [BP],
negative regulation of activation of membrane attack complex [BP] |
| CG_imr90ipsc_promoter_n_PM_16_33_33 |
 |
 |
3 |
0.6 |
4.99E-05 |
EGR2,
PBXIP1,
ADRA1D,
WASF2,
HTR1D |
multicellular organismal development [BP],
adenylate cyclase-modulating G-protein coupled receptor signaling pathway [BP],
G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [BP],
response to insulin stimulus [BP] |
| CG_imr90ipsc_promoter_n_PM_12_344_7 |
 |
 |
2 |
0.4 |
1.66E-04 |
DCAF12,
ZBP1,
TICAM1,
VCP |
protein ubiquitination [BP],
left-handed Z-DNA binding [MF],
positive regulation of type I interferon production [BP] |
| CG_imr90ipsc_promoter_n_PM_12_209_8 |
 |
 |
3 |
0.6 |
6.50E-05 |
MAP2K2 |
regulation of Golgi inheritance [BP],
peptidyl-serine autophosphorylation [BP] |
| CG_imr90ipsc_promoter_n_PM_14_96_23 |
 |
 |
7 |
1.0 |
4.93E-05 |
ENG,
GLA |
negative regulation of nitric-oxide synthase activity [BP] |
| CG_imr90ipsc_promoter_n_PM_12_371_13 |
 |
 |
3 |
0.6 |
1.11E-04 |
ADAM8,
EDN2 |
positive regulation of neutrophil extravasation [BP],
positive regulation of fibronectin-dependent thymocyte migration [BP],
dense core granule membrane [CC],
alpha9-beta1 integrin-ADAM8 complex [CC],
hormonal regulation of the force of heart contraction [BP],
positive regulation of eosinophil migration [BP] |
| CG_imr90ipsc_promoter_n_PM_12_151_16 |
 |
 |
2 |
0.4 |
4.49E-05 |
MBOAT4 |
peptidyl-serine octanoylation [BP],
serine O-acyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_302_7 |
 |
 |
2 |
0.4 |
1.07E-04 |
PLA2G6,
BRF1,
GRIN2B |
transcription factor TFIIIB complex [CC],
memory [BP],
learning or memory [BP] |
| CG_imr90ipsc_promoter_n_PM_12_269_9 |
 |
 |
3 |
0.4 |
1.31E-05 |
SLC25A19 |
deoxynucleotide transport [BP],
deoxynucleotide transmembrane transporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_101_28 |
 |
 |
4 |
0.8 |
5.30E-05 |
RLIM,
SIGMAR1,
ACAD11 |
very-long-chain-acyl-CoA dehydrogenase activity [MF],
ergosterol biosynthetic process [BP],
random inactivation of X chromosome [BP] |
| CG_imr90ipsc_promoter_n_PM_12_184_10 |
 |
 |
1 |
0.2 |
3.90E-05 |
GSS,
GUCA1B,
MATN1 |
glutathione synthase activity [MF],
body fluid secretion [BP],
growth plate cartilage chondrocyte morphogenesis [BP] |
| CG_imr90ipsc_promoter_n_PM_12_342_5 |
 |
 |
1 |
0.2 |
1.08E-05 |
CYP26B1,
BMP7 |
embryonic limb morphogenesis [BP],
nephrogenic mesenchyme morphogenesis [BP],
positive regulation of tongue muscle cell differentiation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_239_11 |
 |
 |
1 |
0.2 |
4.57E-05 |
SRP68,
ECM2,
CEBPA |
signal recognition particle binding [MF],
collagen V binding [MF],
response to vitamin B2 [BP],
endoplasmic reticulum signal peptide binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_299_25 |
 |
 |
4 |
0.8 |
9.56E-06 |
ABR |
negative regulation of neutrophil degranulation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_108_12 |
 |
 |
2 |
0.4 |
2.73E-05 |
A2M,
PDGFA |
platelet alpha granule lumen [CC],
regulation of branching involved in salivary gland morphogenesis by epithelial-mesenchymal signaling [BP] |
| CG_imr90ipsc_promoter_n_PM_12_322_11 |
 |
 |
2 |
0.4 |
1.62E-04 |
TGDS |
dTDP-glucose 4,6-dehydratase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_43_14 |
 |
 |
4 |
0.8 |
2.88E-05 |
INPP5E,
SYNJ1 |
phosphatidylinositol phosphorylation [BP],
inositol-polyphosphate 5-phosphatase activity [MF],
phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_83_10 |
 |
 |
4 |
0.8 |
3.05E-05 |
MED1 |
androgen biosynthetic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_340_8 |
 |
 |
1 |
0.2 |
1.34E-04 |
QRFP |
orexigenic neuropeptide QRFP receptor binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_35_4 |
 |
 |
1 |
0.2 |
4.55E-05 |
MSRB1,
HMGCS1 |
organic acid binding [MF],
response to tellurium ion [BP],
methionine-R-sulfoxide reductase activity [MF],
response to low light intensity stimulus [BP] |
| CG_imr90ipsc_promoter_n_PM_16_35_42 |
 |
 |
4 |
0.8 |
3.81E-05 |
TCEA1 |
regulation of DNA-dependent transcription, elongation [BP] |
| CG_imr90ipsc_promoter_n_PM_14_40_12 |
 |
 |
5 |
0.8 |
2.95E-05 |
GDE1,
MAP6D1 |
glycerophosphoinositol glycerophosphodiesterase activity [MF],
N-terminal peptidyl-L-cysteine N-palmitoylation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_16_9 |
 |
 |
4 |
0.8 |
1.17E-04 |
DPP4,
CD47 |
extracellular vesicular exosome [CC] |
| CG_imr90ipsc_promoter_n_PM_12_207_14 |
 |
 |
3 |
0.6 |
3.09E-04 |
PLXNB1 |
semaphorin-plexin signaling pathway involved in bone trabecula morphogenesis [BP] |
| CG_imr90ipsc_promoter_n_PM_12_38_8 |
 |
 |
1 |
0.2 |
2.56E-04 |
TKTL2,
GSK3B,
BAIAP2L2 |
negative regulation of type B pancreatic cell development [BP],
hypermethylation of CpG island [BP],
negative regulation of glycogen (starch) synthase activity [BP],
canonical Wnt receptor signaling pathway involved in positive regulation of apoptotic process [BP],
superior temporal gyrus development [BP],
clathrin complex [CC],
transketolase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_283_14 |
 |
 |
2 |
0.4 |
1.79E-04 |
DPM3 |
protein C-linked glycosylation via 2'-alpha-mannosyl-L-tryptophan [BP] |
| CG_imr90ipsc_promoter_n_PM_16_17_38 |
 |
 |
5 |
1.0 |
4.09E-05 |
APOB,
DNAJB1,
CCT4,
SPRY2,
GRB2,
EPS15L1,
TOR2A,
PDLIM7 |
'de novo' posttranslational protein folding [BP],
negative regulation of epidermal growth factor receptor signaling pathway [BP],
chaperone mediated protein folding requiring cofactor [BP],
receptor-mediated endocytosis [BP] |
| CG_imr90ipsc_promoter_n_PM_16_32_33 |
 |
 |
5 |
1.0 |
4.86E-05 |
HRAS,
WASF2,
HBEGF |
Rac protein signal transduction [BP],
positive regulation of wound healing [BP] |
| CG_imr90ipsc_promoter_n_PM_12_198_8 |
 |
 |
2 |
0.4 |
1.09E-04 |
GOLGA8A,
GOLGA8B,
HS3ST6 |
Golgi membrane [CC],
Golgi cisterna membrane [CC],
[heparan sulfate]-glucosamine 3-sulfotransferase 1 activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_153_15 |
 |
 |
4 |
0.6 |
7.55E-05 |
ADRA1A |
pilomotor reflex [BP],
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressure [BP],
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure [BP],
positive regulation of the force of heart contraction by epinephrine-norepinephrine [BP],
alpha1-adrenergic receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_263_14 |
 |
 |
3 |
0.4 |
3.90E-05 |
EXOSC10 |
nuclear retention of unspliced pre-mRNA at the site of transcription [BP] |
| CG_imr90ipsc_promoter_n_PM_12_348_8 |
 |
 |
2 |
0.4 |
7.69E-05 |
TRPV3,
TRAPPC8 |
negative regulation of hair cycle [BP],
ER to Golgi vesicle-mediated transport [BP] |
| CG_imr90ipsc_promoter_n_PM_14_102_15 |
 |
 |
1 |
0.2 |
5.47E-05 |
CEBPA,
FHIT,
HYAL2,
CST3 |
negative regulation of blood vessel remodeling [BP],
bis(5'-adenosyl)-triphosphatase activity [MF],
response to vitamin B2 [BP],
negative regulation of elastin catabolic process [BP],
negative regulation of histolysis [BP],
negative regulation of collagen catabolic process [BP],
receptor signaling protein tyrosine kinase inhibitor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_393_8 |
 |
 |
2 |
0.4 |
2.37E-04 |
KCNJ1,
BAZ2A |
heterochromatin assembly involved in chromatin silencing [BP],
regulation of G-protein activated inward rectifier potassium channel activity [BP] |
| CG_imr90ipsc_promoter_n_PM_12_149_12 |
 |
 |
2 |
0.4 |
4.09E-05 |
EIF2AK2,
SCIMP,
TNFSF4,
LMF1 |
protein secretion [BP],
uropod membrane [CC],
tetraspanin-enriched microdomain [CC],
chemokine (C-C motif) ligand 11 production [BP],
interleukin-4-dependent isotype switching to IgE isotypes [BP],
evasion or tolerance by virus of host immune response [BP],
memory T cell activation [BP],
positive regulation of CD4-positive, alpha beta T cell costimulation [BP] |
| CG_imr90ipsc_promoter_n_PM_14_20_4 |
 |
 |
1 |
0.2 |
3.48E-05 |
SUMO1 |
protein localization to nuclear pore [BP] |
| CG_imr90ipsc_promoter_n_PM_12_218_12 |
 |
 |
3 |
0.6 |
1.13E-04 |
UBE2N,
PKD1 |
positive regulation of histone modification [BP],
metanephric distal tubule morphogenesis [BP] |
| CG_imr90ipsc_promoter_n_PM_14_63_7 |
 |
 |
3 |
0.6 |
1.26E-05 |
ANK1 |
maintenance of epithelial cell apical/basal polarity [BP] |
| CG_imr90ipsc_promoter_n_PM_12_145_10 |
 |
 |
1 |
0.2 |
8.48E-05 |
ALG5,
UGDH |
UDP-glucose 6-dehydrogenase activity [MF],
dolichyl-phosphate beta-glucosyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_22_8 |
 |
 |
4 |
0.8 |
6.12E-05 |
CYGB,
PRDX2,
FTCD,
NOXO1 |
peroxidase activity [MF],
formimidoyltetrahydrofolate cyclodeaminase activity [MF],
superoxide metabolic process [BP],
antioxidant activity [MF],
glutamate formimidoyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_368_7 |
 |
 |
3 |
0.6 |
3.32E-05 |
TRMT61B |
mitochondrial tRNA methylation [BP],
tRNA (adenine-N1-)-methyltransferase activity [MF],
tRNA (m1A) methyltransferase complex [CC] |
| CG_imr90ipsc_promoter_n_PM_14_24_7 |
 |
 |
3 |
0.6 |
1.09E-05 |
CSAD |
taurine biosynthetic process [BP],
sulfinoalanine decarboxylase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_192_7 |
 |
 |
2 |
0.4 |
2.83E-04 |
OBSL1,
MYL2 |
cardiac myofibril assembly [BP] |
| CG_imr90ipsc_promoter_n_PM_14_55_10 |
 |
 |
5 |
1.0 |
1.36E-05 |
ACACA |
acetyl-CoA carboxylase activity [MF],
malonyl-CoA biosynthetic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_48_9 |
 |
 |
2 |
0.4 |
1.34E-04 |
ABI1,
ADAMTS8,
NOTCH2,
DOHH,
GAS6,
ENG |
cell proliferation [BP],
negative regulation of cell proliferation [BP],
regulation of cell proliferation [BP],
determination of left/right symmetry [BP],
low affinity phosphate transmembrane transporter activity [MF],
cellular response to vitamin K [BP],
negative regulation of renal albumin absorption [BP],
protein tyrosine kinase activator activity [MF],
negative regulation of oligodendrocyte apoptotic process [BP],
deoxyhypusine monooxygenase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_247_13 |
 |
 |
3 |
0.6 |
6.99E-05 |
MYLK3,
LCT |
lactase activity [MF],
glycosylceramidase activity [MF],
regulation of vascular permeability involved in acute inflammatory response [BP] |
| CG_imr90ipsc_promoter_n_PM_12_75_6 |
 |
 |
3 |
0.6 |
6.59E-05 |
SLC25A19 |
deoxynucleotide transport [BP],
deoxynucleotide transmembrane transporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_24_11 |
 |
 |
2 |
0.4 |
6.70E-05 |
DLC1,
ADRA1A |
negative regulation of Rho protein signal transduction [BP] |
| CG_imr90ipsc_promoter_n_PM_12_360_11 |
 |
 |
2 |
0.4 |
1.19E-05 |
TRMT112 |
peptidyl-glutamine methylation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_329_9 |
 |
 |
3 |
0.6 |
1.32E-04 |
DCAKD |
dephospho-CoA kinase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_292_20 |
 |
 |
2 |
0.4 |
1.16E-04 |
ACVR1C,
NCOR2 |
nodal binding [MF],
regulation of cellular ketone metabolic process by negative regulation of transcription from RNA polymerase II promoter [BP] |
| CG_imr90ipsc_promoter_n_PM_14_47_6 |
 |
 |
2 |
0.4 |
3.80E-05 |
ECSIT |
oxidoreductase activity, acting on NAD(P)H [MF] |
| CG_imr90ipsc_promoter_n_PM_12_397_6 |
 |
 |
3 |
0.6 |
1.89E-04 |
SHPK |
cellular response to interleukin-13 [BP],
sedoheptulokinase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_246_15 |
 |
 |
2 |
0.4 |
1.34E-04 |
RAB3A,
PSRC1 |
maintenance of presynaptic active zone structure [BP],
spindle microtubule [CC] |
| CG_imr90ipsc_promoter_n_PM_12_170_6 |
 |
 |
3 |
0.4 |
6.13E-05 |
APMAP,
GAMT,
DICER1,
CELF1,
PDGFRB |
multicellular organism growth [BP],
cardiac muscle cell development [BP],
strictosidine synthase activity [MF],
cell migration involved in coronary angiogenesis [BP],
guanidinoacetate N-methyltransferase activity [MF],
RNA interference [BP] |
| CG_imr90ipsc_promoter_n_PM_12_13_8 |
 |
 |
4 |
0.6 |
6.51E-05 |
AGXT2,
COL16A1 |
alanine-glyoxylate transaminase activity [MF],
collagen type XVI [CC],
glycine biosynthetic process, by transamination of glyoxylate [BP],
glyoxylate catabolic process [BP],
L-alanine catabolic process, by transamination [BP],
beta-alanine-pyruvate transaminase activity [MF],
(R)-3-amino-2-methylpropionate-pyruvate transaminase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_172_6 |
 |
 |
2 |
0.4 |
1.21E-04 |
ARSA,
NDUFAB1 |
ACP phosphopantetheine attachment site binding involved in fatty acid biosynthetic process [MF],
cerebroside-sulfatase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_306_4 |
 |
 |
1 |
0.2 |
1.30E-04 |
INO80,
TXN |
positive regulation of DNA replication involved in S phase [BP],
response to thyroxine stimulus [BP] |
| CG_imr90ipsc_promoter_n_PM_12_315_11 |
 |
 |
2 |
0.4 |
5.53E-06 |
PRKCQ |
positive regulation of T-helper 2 cell activation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_240_14 |
 |
 |
1 |
0.2 |
6.23E-05 |
PLAUR,
HGD,
GPX1 |
U-plasminogen activator receptor activity [MF],
response to symbiotic bacterium [BP],
homogentisate 1,2-dioxygenase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_16_30_60 |
 |
 |
4 |
0.8 |
3.91E-05 |
HDDC3 |
guanosine-3',5'-bis(diphosphate) 3'-diphosphatase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_252_8 |
 |
 |
2 |
0.4 |
2.45E-04 |
ALS2,
TERT |
regulation of endosome size [BP],
telomeric template RNA reverse transcriptase activity [MF],
telomeric RNA binding [MF],
telomere formation via telomerase [BP] |
| CG_imr90ipsc_promoter_n_PM_12_398_6 |
 |
 |
4 |
0.8 |
1.16E-04 |
CPOX,
APMAP,
PTK2,
RACGAP1 |
cytokinesis, actomyosin contractile ring assembly [BP],
cytokinesis, initiation of separation [BP],
netrin-activated signaling pathway [BP],
strictosidine synthase activity [MF],
response to arsenic-containing substance [BP] |
| CG_imr90ipsc_promoter_n_PM_12_295_6 |
 |
 |
1 |
0.2 |
1.98E-04 |
NACC2,
CTTNBP2,
AKR1B1,
CXCR4,
FZD8 |
glyceraldehyde oxidoreductase activity [MF],
negative regulation of G1/S transition of mitotic cell cycle by negative regulation of transcription from RNA polymerase II promoter [BP],
brain development [BP],
myosin light chain binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_175_23 |
 |
 |
2 |
0.4 |
2.83E-05 |
TST,
CYP11A1,
STAT5B |
cholesterol monooxygenase (side-chain-cleaving) activity [MF],
cyanate catabolic process [BP],
response to genistein [BP],
progesterone metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_297_8 |
 |
 |
2 |
0.4 |
9.82E-05 |
NCBP2,
AQP7 |
gene silencing by RNA [BP],
urea channel activity [MF],
ncRNA metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_257_18 |
 |
 |
3 |
0.6 |
1.15E-04 |
TBC1D10A,
EIF2B3 |
guanyl-nucleotide exchange factor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_291_9 |
 |
 |
4 |
0.8 |
2.52E-05 |
NQO1 |
NAD(P)H dehydrogenase (quinone) activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_46_12 |
 |
 |
2 |
0.4 |
7.45E-05 |
DNAJC2,
APTX |
polynucleotide 3'-phosphatase activity [MF],
'de novo' cotranslational protein folding [BP],
DNA 5'-adenosine monophosphate hydrolase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_362_12 |
 |
 |
2 |
0.4 |
1.10E-04 |
ADAT1,
CTSH |
tRNA-specific adenosine deaminase activity [MF],
HLA-A specific activating MHC class I receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_143_8 |
 |
 |
3 |
0.6 |
4.51E-05 |
GALNS |
N-acetylgalactosamine-6-sulfatase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_242_11 |
 |
 |
2 |
0.4 |
6.11E-05 |
LEPRE1 |
procollagen-proline 3-dioxygenase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_88_12 |
 |
 |
2 |
0.4 |
1.45E-04 |
SLIT1,
VCPIP1,
RYK |
negative chemotaxis [BP],
axon extension involved in axon guidance [BP],
Golgi reassembly [BP],
negative regulation of axon extension involved in axon guidance [BP] |
| CG_imr90ipsc_promoter_n_PM_12_47_8 |
 |
 |
3 |
0.6 |
4.71E-05 |
MPO |
hypochlorous acid biosynthetic process [BP] |
| CG_imr90ipsc_promoter_n_PM_16_9_8 |
 |
 |
3 |
0.6 |
5.83E-05 |
GBA,
SLC27A5 |
glucosylceramide catabolic process [BP],
glucosylceramidase activity [MF],
cholate-CoA ligase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_16_36_10 |
 |
 |
3 |
0.6 |
4.53E-05 |
HLCS,
PC |
protein biotinylation [BP],
biotin binding [MF],
histone biotinylation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_18_7 |
 |
 |
3 |
0.6 |
2.03E-04 |
DHX33,
NEK2,
NOC3L |
nucleolus [CC] |
| CG_imr90ipsc_promoter_n_PM_12_22_10 |
 |
 |
3 |
0.6 |
1.62E-04 |
B4GALNT1 |
(N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_304_5 |
 |
 |
2 |
0.4 |
2.62E-04 |
LMOD1,
DST |
actin binding [MF],
H zone [CC] |
| CG_imr90ipsc_promoter_n_PM_12_137_10 |
 |
 |
3 |
0.6 |
1.19E-04 |
SNX3,
HDAC4,
TECPR1,
BNIP3,
ELK4,
VPRBP,
AMOT,
RERE |
phosphatidylinositol-3-phosphate binding [MF],
histone H3 deacetylation [BP],
chromatin remodeling [BP],
signalosome [CC] |
| CG_imr90ipsc_promoter_n_PM_12_141_8 |
 |
 |
3 |
0.6 |
6.33E-05 |
YWHAZ |
histamine secretion by mast cell [BP] |
| CG_imr90ipsc_promoter_n_PM_12_354_22 |
 |
 |
3 |
0.6 |
3.17E-05 |
PPIP5K1,
FASN,
PIF1 |
3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activity [MF],
inositol-1,3,4,5,6-pentakisphosphate kinase activity [MF],
myristoyl-[acyl-carrier-protein] hydrolase activity [MF],
[acyl-carrier-protein] S-malonyltransferase activity [MF],
enoyl-[acyl-carrier-protein] reductase (NADPH, B-specific) activity [MF],
[acyl-carrier-protein] S-acetyltransferase activity [MF],
3-oxoacyl-[acyl-carrier-protein] synthase activity [MF],
ATP-dependent 5'-3' DNA/RNA helicase activity [MF],
palmitoyl-[acyl-carrier-protein] hydrolase activity [MF],
oleoyl-[acyl-carrier-protein] hydrolase activity [MF],
3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activity [MF],
3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity [MF],
diphosphoinositol-pentakisphosphate kinase activity [MF],
single-stranded DNA-dependent ATP-dependent DNA helicase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_335_5 |
 |
 |
1 |
0.2 |
2.15E-05 |
SUMO1 |
protein localization to nuclear pore [BP] |
| CG_imr90ipsc_promoter_n_PM_12_49_5 |
 |
 |
2 |
0.4 |
7.14E-05 |
UXS1 |
UDP-D-xylose biosynthetic process [BP],
UDP-glucuronate decarboxylase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_16_15_9 |
 |
 |
1 |
0.2 |
1.03E-05 |
SHMT1,
LOXL2 |
L-allo-threonine aldolase activity [MF],
glycine biosynthetic process from serine [BP],
protein deamination [BP],
glycine hydroxymethyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_255_10 |
 |
 |
2 |
0.4 |
1.41E-04 |
DOHH,
FOXJ1 |
negative regulation of germinal center formation [BP],
central tolerance induction [BP],
negative regulation of humoral immune response mediated by circulating immunoglobulin [BP],
glomerular parietal epithelial cell development [BP],
deoxyhypusine monooxygenase activity [MF],
positive regulation of lung ciliated cell differentiation [BP],
positive regulation of central B cell tolerance induction [BP] |
| CG_imr90ipsc_promoter_n_PM_12_82_13 |
 |
 |
2 |
0.4 |
6.59E-05 |
DLG4 |
P2Y1 nucleotide receptor binding [MF] |
| CG_imr90ipsc_promoter_n_PM_16_7_7 |
 |
 |
2 |
0.4 |
7.55E-06 |
ST3GAL5 |
neolactotetraosylceramide alpha-2,3-sialyltransferase activity [MF],
lactosylceramide alpha-2,3-sialyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_66_3 |
 |
 |
1 |
0.2 |
1.13E-04 |
NOP14 |
Noc4p-Nop14p complex [CC] |
| CG_imr90ipsc_promoter_n_PM_14_62_5 |
 |
 |
1 |
0.2 |
4.15E-05 |
MAPK3,
PSG9,
USP6NL,
PSG5,
PSG2,
PSG1,
PSG11 |
negative regulation of apolipoprotein binding [BP],
female pregnancy [BP],
Golgi organization [BP] |
| CG_imr90ipsc_promoter_n_PM_12_222_12 |
 |
 |
3 |
0.4 |
3.88E-05 |
MAFB |
rhombomere 6 development [BP] |
| CG_imr90ipsc_promoter_n_PM_12_130_15 |
 |
 |
3 |
0.6 |
5.91E-05 |
BMP10,
PICALM,
SHARPIN,
TACSTD2 |
clathrin heavy chain binding [MF],
negative regulation of cell motility [BP],
regulation of CD40 signaling pathway [BP],
LUBAC complex [CC],
negative regulation of ruffle assembly [BP],
negative regulation of cell migration [BP] |
| CG_imr90ipsc_promoter_n_PM_12_406_21 |
 |
 |
2 |
0.4 |
8.73E-05 |
ARSA,
C5,
ADAMTS8,
TWF1 |
cerebroside-sulfatase activity [MF],
negative regulation of macrophage chemotaxis [BP],
regulation of actin phosphorylation [BP],
low affinity phosphate transmembrane transporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_349_11 |
 |
 |
2 |
0.4 |
1.11E-04 |
GJA5,
UFSP1 |
gap junction channel activity involved in cardiac conduction electrical coupling [MF],
UFM1 hydrolase activity [MF],
AV node cell to bundle of His cell communication by electrical coupling [BP],
gap junction channel activity involved in AV node cell-bundle of His cell electrical coupling [MF],
atrial ventricular junction remodeling [BP] |
| CG_imr90ipsc_promoter_n_PM_14_23_8 |
 |
 |
4 |
0.8 |
5.26E-05 |
LONP1,
BST2,
SRI |
oxidation-dependent protein catabolic process [BP],
negative regulation of egress of virus within host cell [BP],
negative regulation of plasmacytoid dendritic cell cytokine production [BP],
regulation of cell communication by electrical coupling involved in cardiac conduction [BP] |
| CG_imr90ipsc_promoter_n_PM_12_155_20 |
 |
 |
2 |
0.4 |
1.40E-04 |
SNAP91 |
clathrin coat [CC] |
| CG_imr90ipsc_promoter_n_PM_14_31_10 |
 |
 |
5 |
0.8 |
1.09E-04 |
NKX2-5,
ATPBD4 |
proepicardium development [BP],
positive regulation of voltage-gated calcium channel activity [BP],
serum response element binding [MF],
diphthine-ammonia ligase activity [MF],
positive regulation of transcription via serum response element binding [BP],
Purkinje myocyte differentiation [BP],
apoptotic process involved in heart morphogenesis [BP],
atrioventricular node cell development [BP],
right ventricular cardiac muscle tissue morphogenesis [BP],
atrioventricular node cell fate commitment [BP] |
| CG_imr90ipsc_promoter_n_PM_14_60_5 |
 |
 |
1 |
0.2 |
7.33E-05 |
SMURF2,
PCBD1,
GLA |
raffinose alpha-galactosidase activity [MF],
identical protein binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_174_11 |
 |
 |
3 |
0.6 |
9.35E-05 |
C5,
WNT7B,
AXIN1 |
activation of JUN kinase activity [BP],
activation of MAPK activity [BP],
forebrain regionalization [BP] |
| CG_imr90ipsc_promoter_n_PM_12_230_9 |
 |
 |
2 |
0.4 |
8.89E-05 |
ACOX2,
PITPNA,
COL5A2 |
phosphatidylcholine transporter activity [MF],
collagen type V [CC],
pristanoyl-CoA oxidase activity [MF],
stearic acid binding [MF],
3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoyl-CoA 24-hydroxylase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_300_10 |
 |
 |
4 |
0.8 |
1.49E-04 |
TOP1MT,
POLRMT |
mitochondrial nucleoid [CC] |
| CG_imr90ipsc_promoter_n_PM_12_136_12 |
 |
 |
3 |
0.6 |
2.67E-04 |
NLRP10,
PHLDA3,
RAB35 |
dendritic cell migration [BP],
phosphatidylinositol-4,5-bisphosphate binding [MF],
helper T cell enhancement of adaptive immune response [BP] |
| CG_imr90ipsc_promoter_n_PM_14_21_8 |
 |
 |
1 |
0.2 |
3.87E-05 |
LTA4H |
leukotriene-A4 hydrolase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_127_9 |
 |
 |
2 |
0.4 |
1.62E-04 |
IP6K3,
NOP14,
E2F8,
AUH |
Noc4p-Nop14p complex [CC],
methylglutaconyl-CoA hydratase activity [MF],
inositol hexakisphosphate 6-kinase activity [MF],
cell cycle comprising mitosis without cytokinesis [BP] |
| CG_imr90ipsc_promoter_n_PM_12_358_11 |
 |
 |
2 |
0.4 |
4.38E-05 |
IPMK,
SULT2A1,
HID1 |
bile-salt sulfotransferase activity [MF],
response to brefeldin A [BP],
inositol tetrakisphosphate 3-kinase activity [MF],
inositol-1,4,5-trisphosphate 6-kinase activity [MF],
extrinsic to Golgi membrane [CC] |
| CG_imr90ipsc_promoter_n_PM_12_7_11 |
 |
 |
5 |
0.8 |
7.91E-05 |
NUP62,
DEAF1,
ADAMTS1 |
anatomical structure morphogenesis [BP],
negative regulation of cell proliferation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_211_13 |
 |
 |
2 |
0.4 |
9.59E-05 |
S100A7 |
positive regulation of granulocyte chemotaxis [BP] |
| CG_imr90ipsc_promoter_n_PM_12_123_13 |
 |
 |
2 |
0.4 |
2.40E-04 |
COA3 |
positive regulation of mitochondrial translation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_357_8 |
 |
 |
3 |
0.6 |
2.06E-04 |
SLC25A17 |
ADP transmembrane transporter activity [MF],
FMN transmembrane transporter activity [MF],
NAD transport [BP],
FAD transmembrane transporter activity [MF],
NAD transporter activity [MF],
ATP transmembrane transporter activity [MF],
coenzyme A transmembrane transporter activity [MF],
AMP transmembrane transporter activity [MF],
coenzyme A transmembrane transport [BP],
FAD transmembrane transport [BP],
ADP transport [BP],
AMP transport [BP] |
| CG_imr90ipsc_promoter_n_PM_14_25_8 |
 |
 |
7 |
1.0 |
2.66E-05 |
MB,
LONP1 |
oxidation-dependent protein catabolic process [BP],
slow-twitch skeletal muscle fiber contraction [BP] |
| CG_imr90ipsc_promoter_n_PM_12_220_11 |
 |
 |
2 |
0.4 |
2.52E-04 |
ISYNA1,
DNMT3A |
S-adenosylhomocysteine metabolic process [BP],
inositol-3-phosphate synthase activity [MF],
DNA (cytosine-5-)-methyltransferase activity, acting on CpG substrates [MF] |
| CG_imr90ipsc_promoter_n_PM_14_27_7 |
 |
 |
2 |
0.4 |
8.30E-05 |
AK3 |
ITP metabolic process [BP],
nucleoside triphosphate adenylate kinase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_359_7 |
 |
 |
3 |
0.6 |
1.65E-04 |
INTS1,
STX1A |
myosin head/neck binding [MF],
U2 snRNA 3'-end processing [BP] |
| CG_imr90ipsc_promoter_n_PM_12_217_12 |
 |
 |
2 |
0.4 |
4.00E-05 |
HMGCS1 |
organic acid binding [MF],
response to tellurium ion [BP],
response to low light intensity stimulus [BP] |
| CG_imr90ipsc_promoter_n_PM_12_392_9 |
 |
 |
2 |
0.4 |
5.36E-05 |
MGLL,
SPTLC1,
UFSP1 |
UFM1 hydrolase activity [MF],
phospholipid metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_15_17 |
 |
 |
4 |
0.8 |
1.28E-04 |
ALX4,
TAPT1,
PLAGL2 |
post-embryonic development [BP] |
| CG_imr90ipsc_promoter_n_PM_14_44_9 |
 |
 |
2 |
0.4 |
1.00E-04 |
FA2H,
BAZ2A |
heterochromatin assembly involved in chromatin silencing [BP],
sebaceous gland cell differentiation [BP],
fatty acid alpha-hydroxylase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_125_16 |
 |
 |
4 |
0.8 |
5.81E-05 |
DDO,
TACR1,
CNOT4,
EIF4E |
nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay [BP],
insemination [BP],
substance P receptor activity [MF],
eukaryotic initiation factor 4G binding [MF],
nuclear-transcribed mRNA poly(A) tail shortening [BP],
D-aspartate oxidase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_338_10 |
 |
 |
1 |
0.2 |
7.66E-05 |
SLC35D1,
PMCH |
melanin-concentrating hormone activity [MF],
UDP-glucuronic acid transmembrane transporter activity [MF],
UDP-N-acetylgalactosamine transport [BP],
UDP-glucuronic acid transport [BP],
UDP-N-acetylgalactosamine transmembrane transporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_129_8 |
 |
 |
1 |
0.2 |
9.02E-05 |
WNT7B |
establishment or maintenance of polarity of embryonic epithelium [BP],
outer medullary collecting duct development [BP] |
| CG_imr90ipsc_promoter_n_PM_12_391_12 |
 |
 |
1 |
0.2 |
1.27E-04 |
TGFB3 |
detection of hypoxia [BP] |
| CG_imr90ipsc_promoter_n_PM_12_94_13 |
 |
 |
4 |
0.8 |
1.35E-04 |
SCARA5,
POU2F2 |
immunoglobulin secretion involved in immune response [BP],
ferritin receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_264_10 |
 |
 |
2 |
0.2 |
4.00E-05 |
ATP4A,
ATP6V1E1 |
ATP hydrolysis coupled proton transport [BP] |
| CG_imr90ipsc_promoter_n_PM_12_396_6 |
 |
 |
2 |
0.4 |
1.48E-05 |
ATG5,
ULK2 |
otolith development [BP],
pre-autophagosomal structure membrane [CC],
response to starvation [BP],
autophagy [BP] |
| CG_imr90ipsc_promoter_n_PM_14_8_18 |
 |
 |
3 |
0.6 |
3.87E-05 |
UXS1,
TRMT1L |
tRNA (guanine-N2-)-methyltransferase activity [MF],
UDP-D-xylose biosynthetic process [BP],
UDP-glucuronate decarboxylase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_356_10 |
 |
 |
3 |
0.6 |
1.50E-04 |
APMAP,
SPDEF,
HIGD1A,
BCL11B,
IL2,
CLN3,
TAF5L,
MYOG,
HDDC3,
BMP7 |
transcription from RNA polymerase II promoter [BP],
guanosine-3',5'-bis(diphosphate) 3'-diphosphatase activity [MF],
strictosidine synthase activity [MF],
core promoter proximal region sequence-specific DNA binding [MF],
kappa-type opioid receptor binding [MF],
negative regulation of apoptotic process [BP],
negative regulation of cell death [BP],
positive regulation of transcription from RNA polymerase II promoter [BP] |
| CG_imr90ipsc_promoter_n_PM_12_171_7 |
 |
 |
3 |
0.4 |
1.60E-04 |
POU4F1,
NCAPD3,
NR4A2 |
habenula development [BP],
nuclear condensin complex [CC],
proprioception involved in equilibrioception [BP] |
| CG_imr90ipsc_promoter_n_PM_14_2_9 |
 |
 |
2 |
0.4 |
7.56E-05 |
CD8A |
cytotoxic T cell differentiation [BP] |
| CG_imr90ipsc_promoter_n_PM_16_2_103 |
 |
 |
6 |
1.0 |
6.54E-05 |
PRPS1L1,
BBC3,
PRPSAP1,
EIF2AK3,
PLA2G6 |
response to endoplasmic reticulum stress [BP],
ribose phosphate diphosphokinase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_262_13 |
 |
 |
3 |
0.4 |
8.32E-05 |
DOHH,
SYCE3,
DCUN1D3,
AZI1,
PAFAH1B3,
BCL2L1 |
response to gamma radiation [BP],
spermatogenesis [BP],
deoxyhypusine monooxygenase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_199_5 |
 |
 |
1 |
0.2 |
6.91E-05 |
GTF2F1 |
transcription factor TFIIF complex [CC] |
| CG_imr90ipsc_promoter_n_PM_16_20_21 |
 |
 |
3 |
0.6 |
3.98E-05 |
COBL,
FZD5,
WNT3 |
Spemann organizer formation [BP],
embryonic pattern specification [BP],
collateral sprouting in absence of injury [BP] |
| CG_imr90ipsc_promoter_n_PM_14_6_7 |
 |
 |
1 |
0.2 |
3.82E-05 |
SPI1 |
granulocyte differentiation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_216_5 |
 |
 |
1 |
0.2 |
6.48E-05 |
CYP7B1,
TERT,
TUT1 |
25-hydroxycholesterol 7alpha-hydroxylase activity [MF],
telomeric template RNA reverse transcriptase activity [MF],
telomeric RNA binding [MF],
RNA uridylyltransferase activity [MF],
oxysterol 7-alpha-hydroxylase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_20_10 |
 |
 |
2 |
0.4 |
1.56E-04 |
CNOT7,
CDK5RAP2 |
negative regulation of centriole replication [BP],
CCR4-NOT complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_403_11 |
 |
 |
4 |
0.8 |
7.50E-05 |
PARK2,
AVP |
negative regulation of release of cytochrome c from mitochondria [BP],
V1B vasopressin receptor binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_308_17 |
 |
 |
4 |
0.8 |
2.85E-05 |
YWHAG |
protein kinase C inhibitor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_48_15 |
 |
 |
2 |
0.4 |
1.20E-04 |
ALKBH1 |
RNA repair [BP],
methylcytosine dioxygenase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_60_11 |
 |
 |
2 |
0.4 |
5.11E-05 |
ACVR1C,
TOLLIP,
MCRS1,
E2F6 |
nodal binding [MF],
interleukin-18 receptor complex [CC],
MLL1 complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_214_8 |
 |
 |
2 |
0.4 |
2.59E-04 |
LIFR |
leukemia inhibitory factor receptor activity [MF],
growth factor binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_190_10 |
 |
 |
2 |
0.4 |
1.82E-04 |
CELF1,
TK2 |
deoxycytidine kinase activity [MF],
thymidine kinase activity [MF],
BRE binding [MF],
deoxycytidine metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_32_3 |
 |
 |
3 |
0.6 |
1.79E-04 |
NUDT14,
EARS2 |
glutamate-tRNA(Gln) ligase activity [MF],
UDP-sugar diphosphatase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_154_13 |
 |
 |
2 |
0.4 |
2.21E-04 |
CST11 |
defense response to bacterium [BP] |
| CG_imr90ipsc_promoter_n_PM_12_101_10 |
 |
 |
1 |
0.2 |
1.74E-05 |
ENG,
RNF41 |
protein tag [MF],
interleukin-3 receptor binding [MF],
endothelial microparticle [CC],
erythropoietin receptor binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_107_7 |
 |
 |
3 |
0.6 |
1.83E-04 |
CASP3,
FOXP3 |
nuclear fragmentation involved in apoptotic nuclear change [BP],
positive regulation of peripheral T cell tolerance induction [BP],
B cell homeostasis [BP],
positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation [BP],
T cell homeostasis [BP],
negative regulation of T cell proliferation [BP],
negative regulation of activated T cell proliferation [BP],
negative regulation of histone deacetylation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_395_13 |
 |
 |
1 |
0.2 |
2.38E-05 |
SYNE4,
NR3C1,
MEX3D |
integral to nuclear outer membrane [CC],
mRNA localization resulting in posttranscriptional regulation of gene expression [BP],
glucocorticoid receptor activity [MF],
mRNA destabilization [BP] |
| CG_imr90ipsc_promoter_n_PM_12_173_7 |
 |
 |
1 |
0.2 |
1.16E-04 |
VPS4B,
ARSD |
lysosome [CC] |
| CG_imr90ipsc_promoter_n_PM_12_110_10 |
 |
 |
1 |
0.2 |
4.58E-05 |
STRA6 |
alveolar primary septum development [BP],
vitamin A import [BP] |
| CG_imr90ipsc_promoter_n_PM_12_163_15 |
 |
 |
2 |
0.4 |
4.99E-05 |
GRIN2A,
CYP2A6,
ADA,
TICAM1 |
positive regulation of B cell proliferation [BP],
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen [MF],
sleep [BP] |
| CG_imr90ipsc_promoter_n_PM_12_379_5 |
 |
 |
2 |
0.4 |
1.96E-05 |
CLPX,
NFIB |
negative regulation of mesenchymal cell proliferation involved in lung development [BP],
mitochondrial endopeptidase Clp complex [CC],
negative regulation of epithelial cell proliferation involved in lung morphogenesis [BP] |
| CG_imr90ipsc_promoter_n_PM_12_275_14 |
 |
 |
3 |
0.6 |
4.32E-05 |
SLC27A5,
AURKAIP1 |
positive regulation of proteolysis [BP],
cholate-CoA ligase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_282_13 |
 |
 |
2 |
0.4 |
6.45E-05 |
ACTC1 |
actomyosin, actin part [CC],
skeletal muscle thin filament assembly [BP] |
| CG_imr90ipsc_promoter_n_PM_12_93_11 |
 |
 |
2 |
0.4 |
1.16E-04 |
S100A7,
SEPHS2 |
positive regulation of granulocyte chemotaxis [BP],
selenide, water dikinase activity [MF],
selenocysteine biosynthetic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_44_6 |
 |
 |
3 |
0.6 |
2.48E-04 |
CYP39A1 |
steroid 7-alpha-hydroxylase activity [MF],
24-hydroxycholesterol 7alpha-hydroxylase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_249_5 |
 |
 |
2 |
0.4 |
1.54E-04 |
HSD17B11 |
androgen catabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_63_7 |
 |
 |
2 |
0.4 |
1.58E-05 |
IL9 |
positive regulation of interleukin-5 biosynthetic process [BP],
interleukin-9 receptor binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_319_8 |
 |
 |
2 |
0.4 |
3.06E-04 |
TFF3,
ABCB6 |
apical lamina of hyaline layer [CC],
heme-transporting ATPase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_237_6 |
 |
 |
2 |
0.4 |
2.03E-04 |
MMS19,
IDS |
iduronate-2-sulfatase activity [MF],
phosphorelay signal transduction system [BP] |
| CG_imr90ipsc_promoter_n_PM_12_274_4 |
 |
 |
1 |
0.2 |
7.19E-05 |
ERCC3,
CYP27B1,
EIF4E |
eukaryotic initiation factor 4G binding [MF],
calcidiol 1-monooxygenase activity [MF],
nucleotide-excision repair, DNA duplex unwinding [BP] |
| CG_imr90ipsc_promoter_n_PM_12_261_12 |
 |
 |
3 |
0.6 |
2.70E-04 |
PES1 |
preribosome, large subunit precursor [CC],
maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) [BP],
PeBoW complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_74_11 |
 |
 |
1 |
0.2 |
1.27E-04 |
GPR18,
OXGR1 |
G-protein coupled purinergic nucleotide receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_272_7 |
 |
 |
2 |
0.4 |
7.74E-05 |
CYP51A1,
DNAJC2 |
sterol 14-demethylase activity [MF],
cholesterol biosynthetic process via 24,25-dihydrolanosterol [BP],
'de novo' cotranslational protein folding [BP] |
| CG_imr90ipsc_promoter_n_PM_12_42_6 |
 |
 |
1 |
0.2 |
1.33E-04 |
CHML |
Rab-protein geranylgeranyltransferase complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_233_9 |
 |
 |
1 |
0.2 |
1.21E-04 |
SLC1A2,
CDK6,
MTSS1 |
negative regulation of epithelial cell proliferation [BP],
epithelial cell proliferation involved in renal tubule morphogenesis [BP],
glutamate:sodium symporter activity [MF],
cell dedifferentiation [BP],
ruffle [CC] |
| CG_imr90ipsc_promoter_n_PM_12_124_8 |
 |
 |
2 |
0.4 |
1.12E-04 |
MZB1,
GNPTAB |
protein secretion [BP],
UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity [MF],
positive regulation of immunoglobulin biosynthetic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_152_17 |
 |
 |
4 |
0.6 |
8.56E-05 |
ST3GAL5 |
neolactotetraosylceramide alpha-2,3-sialyltransferase activity [MF],
lactosylceramide alpha-2,3-sialyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_9_22 |
 |
 |
4 |
0.6 |
4.03E-05 |
P2RY12,
CCL19 |
ADP receptor activity [MF],
positive regulation of dendritic cell dendrite assembly [BP] |
| CG_imr90ipsc_promoter_n_PM_16_52_12 |
 |
 |
2 |
0.4 |
9.18E-05 |
MYL2,
NTN4,
SOD2,
ARNT,
MYH10 |
aryl hydrocarbon receptor activity [MF],
cardiac myofibril assembly [BP],
vasodilation by acetylcholine involved in regulation of systemic arterial blood pressure [BP],
erythrophore differentiation [BP],
myosin complex [CC],
age-dependent response to reactive oxygen species [BP],
muscle cell fate specification [BP],
regulation of branching involved in salivary gland morphogenesis by extracellular matrix-epithelial cell signaling [BP] |
| CG_imr90ipsc_promoter_n_PM_12_204_8 |
 |
 |
1 |
0.2 |
6.56E-05 |
CTDNEP1,
PPT1,
SCARB1,
CLN6,
HNRNPH1,
CACTIN,
SNW1 |
positive regulation of triglyceride biosynthetic process [BP],
catalytic step 2 spliceosome [CC],
lysosomal lumen acidification [BP] |
| CG_imr90ipsc_promoter_n_PM_12_118_11 |
 |
 |
2 |
0.4 |
5.01E-04 |
SHH |
metanephric mesenchymal cell proliferation involved in metanephros development [BP],
regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry [BP],
negative regulation of ureter smooth muscle cell differentiation [BP],
right lung development [BP],
positive regulation of immature T cell proliferation in thymus [BP],
negative regulation of cholesterol efflux [BP],
multicellular structure septum development [BP],
epithelial-mesenchymal signaling involved in prostate gland development [BP],
positive regulation of kidney smooth muscle cell differentiation [BP],
CD4-positive or CD8-positive, alpha-beta T cell lineage commitment [BP],
intein-mediated protein splicing [BP],
left lung development [BP],
positive regulation of mesenchymal cell proliferation involved in ureter development [BP],
positive regulation of skeletal muscle cell proliferation [BP],
negative regulation of kidney smooth muscle cell differentiation [BP],
positive regulation of epithelial cell proliferation involved in prostate gland development [BP],
primary prostatic bud elongation [BP],
mesenchymal cell proliferation involved in lung development [BP],
bud outgrowth involved in lung branching [BP],
smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation [BP],
Bergmann glial cell differentiation [BP],
mesenchymal smoothened signaling pathway involved in prostate gland development [BP],
prostate epithelial cord elongation [BP],
regulation of mesenchymal cell proliferation involved in prostate gland development [BP],
positive regulation of hh target transcription factor activity [BP],
positive regulation of ureter smooth muscle cell differentiation [BP],
positive regulation of sclerotome development [BP] |
| CG_imr90ipsc_promoter_n_PM_12_80_4 |
 |
 |
1 |
0.2 |
1.23E-04 |
RNGTT,
DBT,
MFSD10 |
dihydrolipoyllysine-residue (2-methylpropanoyl)transferase activity [MF],
mRNA guanylyltransferase activity [MF],
tetracycline transport [BP],
polynucleotide 5'-phosphatase activity [MF],
tetracycline transporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_77_24 |
 |
 |
2 |
0.4 |
1.05E-04 |
PON1,
GCLC,
CALB1,
PON2,
RRM2B,
CER1,
RS1,
SDC1 |
ureteric bud development [BP],
arylesterase activity [MF],
response to oxidative stress [BP],
retina layer formation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_284_11 |
 |
 |
2 |
0.4 |
6.92E-05 |
MTERF |
termination of mitochondrial transcription [BP] |
| CG_imr90ipsc_promoter_n_PM_12_382_12 |
 |
 |
4 |
0.6 |
1.25E-04 |
SMG6,
DICER1,
NCAPD3,
NKX6-2 |
spinal cord motor neuron differentiation [BP],
endoribonuclease activity [MF],
nuclear condensin complex [CC],
positive regulation of glial cell differentiation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_126_8 |
 |
 |
2 |
0.4 |
1.83E-04 |
B4GALT1 |
lactose biosynthetic process [BP],
glycocalyx [CC],
positive regulation of apoptotic process involved in mammary gland involution [BP] |
| CG_imr90ipsc_promoter_n_PM_12_383_9 |
 |
 |
4 |
0.6 |
1.11E-04 |
ATE1,
SUPT4H1 |
protein arginylation [BP],
arginyltransferase activity [MF],
DSIF complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_206_15 |
 |
 |
1 |
0.2 |
1.92E-04 |
CYP2D6 |
negative regulation of cellular organofluorine metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_213_6 |
 |
 |
2 |
0.4 |
9.64E-05 |
RIT1,
MYO5B,
ASPM |
negative regulation of asymmetric cell division [BP],
calmodulin binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_273_13 |
 |
 |
2 |
0.4 |
9.27E-05 |
RARG,
GBA2 |
glucosylceramidase activity [MF],
Harderian gland development [BP],
growth plate cartilage chondrocyte growth [BP] |
| CG_imr90ipsc_promoter_n_PM_12_378_13 |
 |
 |
2 |
0.4 |
1.35E-04 |
SLC25A29 |
acyl carnitine transmembrane transporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_317_8 |
 |
 |
2 |
0.4 |
2.81E-04 |
PPP4R1,
TMEM86B,
ERCC3 |
dATP binding [MF],
alkenylglycerophosphoethanolamine hydrolase activity [MF],
SSL2-core TFIIH complex [CC],
alkenylglycerophosphocholine hydrolase activity [MF],
nucleotide-excision repair, DNA duplex unwinding [BP],
protein phosphatase type 4 regulator activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_361_18 |
 |
 |
3 |
0.6 |
6.25E-05 |
PCYT2 |
ethanolamine-phosphate cytidylyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_1_6 |
 |
 |
3 |
0.6 |
6.13E-05 |
CLASP1,
SERPINA1 |
response to methanol [BP],
centrosomal corona [CC] |
| CG_imr90ipsc_promoter_n_PM_12_128_9 |
 |
 |
3 |
0.6 |
5.70E-05 |
SUCLG1,
APMAP |
strictosidine synthase activity [MF],
succinate-CoA ligase complex (GDP-forming) [CC] |
| CG_imr90ipsc_promoter_n_PM_12_64_7 |
 |
 |
2 |
0.4 |
1.80E-05 |
LDHB,
GRIK1 |
positive regulation of gamma-aminobutyric acid secretion [BP],
lactate metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_14_61_11 |
 |
 |
1 |
0.2 |
7.96E-05 |
EPOR |
erythropoietin receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_7_9 |
 |
 |
1 |
0.2 |
1.33E-04 |
CDO1 |
cysteine dioxygenase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_350_5 |
 |
 |
3 |
0.6 |
1.09E-04 |
SGMS1,
PCSK7 |
integral to Golgi membrane [CC] |
| CG_imr90ipsc_promoter_n_PM_12_258_10 |
 |
 |
3 |
0.6 |
2.39E-04 |
SLC4A11,
RILP,
SYTL4,
AUH,
IL10 |
negative regulation of chronic inflammatory response to antigenic stimulus [BP],
phosphoenolpyruvate-dependent sugar phosphotransferase system [BP],
negative regulation of myeloid dendritic cell activation [BP],
borate transmembrane transporter activity [MF],
methylglutaconyl-CoA hydratase activity [MF],
interleukin-10 receptor binding [MF],
borate transport [BP],
negative regulation of interferon-alpha biosynthetic process [BP],
Rab GTPase binding [MF],
borate transmembrane transport [BP] |
| CG_imr90ipsc_promoter_n_PM_12_352_9 |
 |
 |
2 |
0.4 |
1.58E-05 |
OSM,
TONSL |
oncostatin-M receptor binding [MF],
FACT complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_413_3 |
 |
 |
3 |
0.6 |
1.12E-04 |
PHOSPHO1 |
phosphocholine phosphatase activity [MF],
phosphoethanolamine phosphatase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_23_8 |
 |
 |
3 |
0.6 |
2.21E-04 |
ST6GALNAC4,
AADAT,
TBXA2R |
positive regulation of blood pressure [BP],
(alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl-galactosaminide 6-alpha-sialyltransferase activity [MF],
thromboxane A2 receptor activity [MF],
2-aminoadipate transaminase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_5_4 |
 |
 |
2 |
0.4 |
7.59E-05 |
FGF8 |
cell migration involved in mesendoderm migration [BP] |
| CG_imr90ipsc_promoter_n_PM_16_6_15 |
 |
 |
4 |
0.8 |
6.66E-05 |
STOML2,
ANKH |
inorganic diphosphate transmembrane transporter activity [MF],
cardiolipin binding [MF] |
| CG_imr90ipsc_promoter_n_PM_14_78_6 |
 |
 |
2 |
0.4 |
2.04E-05 |
AADAT,
CARD8 |
NACHT domain binding [MF],
2-aminoadipate transaminase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_16_22_23 |
 |
 |
3 |
0.6 |
6.05E-05 |
MPP7 |
signaling adaptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_99_6 |
 |
 |
2 |
0.4 |
5.55E-05 |
TMEM173 |
cyclic-di-GMP binding [MF] |
| CG_imr90ipsc_promoter_n_PM_14_35_12 |
 |
 |
3 |
0.6 |
7.11E-05 |
GCSH,
SLC11A2 |
vanadium ion transmembrane transporter activity [MF],
paraferritin complex [CC],
nickel cation transport [BP],
cadmium ion transmembrane transporter activity [MF],
ferrous iron import [BP],
lead ion transport [BP],
glycine decarboxylation via glycine cleavage system [BP],
ferrous iron transport [BP],
nickel cation transmembrane transport [BP],
lead ion transmembrane transporter activity [MF],
vanadium ion transport [BP] |
| CG_imr90ipsc_promoter_n_PM_12_277_4 |
 |
 |
2 |
0.4 |
9.00E-05 |
BAAT,
PKD1 |
bile acid conjugation [BP],
long-chain acyl-CoA hydrolase activity [MF],
metanephric distal tubule morphogenesis [BP],
glycine N-choloyltransferase activity [MF],
very long chain acyl-CoA hydrolase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_288_15 |
 |
 |
2 |
0.4 |
9.10E-06 |
GFRA4 |
glial cell-derived neurotrophic factor receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_323_13 |
 |
 |
2 |
0.4 |
5.74E-05 |
FLT4,
DUSP7 |
regulation of blood vessel remodeling [BP],
stress-activated MAPK cascade [BP] |
| CG_imr90ipsc_promoter_n_PM_14_93_8 |
 |
 |
2 |
0.4 |
6.58E-05 |
CYP1A1,
CHCHD3,
USP2,
SLC35B3,
SLC35B2,
STARD7,
DUSP26,
CHCHD2 |
flavonoid 3'-monooxygenase activity [MF],
3'-phosphoadenosine 5'-phosphosulfate transmembrane transporter activity [MF],
mitochondrion [CC],
positive regulation of mitotic cell cycle [BP] |
| CG_imr90ipsc_promoter_n_PM_16_51_20 |
 |
 |
4 |
0.8 |
2.90E-05 |
ITPKB |
positive regulation of Ras protein signal transduction [BP] |
| CG_imr90ipsc_promoter_n_PM_12_84_11 |
 |
 |
2 |
0.4 |
1.88E-04 |
ACSBG1,
SREBF1 |
ovarian follicle atresia [BP],
sterol response element binding [MF] |
| CG_imr90ipsc_promoter_n_PM_14_58_7 |
 |
 |
3 |
0.6 |
4.32E-05 |
PIF1 |
ATP-dependent 5'-3' DNA helicase activity [MF],
single-stranded DNA-dependent ATP-dependent DNA helicase activity [MF],
ATP-dependent 5'-3' DNA/RNA helicase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_229_10 |
 |
 |
3 |
0.6 |
9.32E-05 |
RASGRP2,
FBXO21,
DNA2,
EPHA2,
KCTD13 |
positive regulation of DNA replication [BP],
notochord cell development [BP],
ruffle membrane [CC],
ubiquitin ligase complex [CC],
site-specific endodeoxyribonuclease activity, specific for altered base [MF],
leading edge membrane [CC],
regulation of small GTPase mediated signal transduction [BP],
gamma DNA polymerase complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_28_7 |
 |
 |
2 |
0.4 |
5.50E-05 |
SLC5A6,
LAMA1 |
biotin metabolic process [BP],
laminin-3 complex [CC],
biotin transport [BP],
sodium-dependent multivitamin transmembrane transporter activity [MF],
pantothenate transmembrane transport [BP] |
| CG_imr90ipsc_promoter_n_PM_12_215_8 |
 |
 |
2 |
0.4 |
3.05E-05 |
UNC13D,
SUMO1 |
granuloma formation [BP],
protein localization to nuclear pore [BP] |
| CG_imr90ipsc_promoter_n_PM_12_372_6 |
 |
 |
2 |
0.4 |
2.88E-04 |
RNF41,
TBXA2R |
protein tag [MF],
interleukin-3 receptor binding [MF],
thromboxane A2 receptor activity [MF],
erythropoietin receptor binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_289_8 |
 |
 |
2 |
0.4 |
1.87E-04 |
EPHA2,
SLX4,
DEGS2 |
notochord cell development [BP],
ERCC4-ERCC1 complex [CC],
sphingolipid delta-4 desaturase activity [MF],
Holliday junction resolvase complex [CC],
sphingosine hydroxylase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_16_50_22 |
 |
 |
5 |
1.0 |
1.40E-04 |
MSRB1,
ALDH7A1,
IL12RB1 |
interleukin-23 receptor complex [CC],
interleukin-23-mediated signaling pathway [BP],
interleukin-23 binding [MF],
methionine-R-sulfoxide reductase activity [MF],
interleukin-12 receptor complex [CC],
glycine betaine biosynthetic process from choline [BP],
L-aminoadipate-semialdehyde dehydrogenase activity [MF],
betaine-aldehyde dehydrogenase activity [MF],
interleukin-12 receptor activity [MF],
interleukin-23 receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_8_12 |
 |
 |
2 |
0.4 |
5.79E-05 |
APMAP |
strictosidine synthase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_325_14 |
 |
 |
1 |
0.2 |
1.45E-04 |
PZP,
SERPINA6,
SERPINA10 |
serine-type endopeptidase inhibitor activity [MF],
negative regulation of endopeptidase activity [BP] |
| CG_imr90ipsc_promoter_n_PM_12_401_12 |
 |
 |
2 |
0.4 |
2.40E-05 |
SLC25A29 |
acyl carnitine transmembrane transporter activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_374_8 |
 |
 |
3 |
0.6 |
1.46E-04 |
PLA2G1B |
interleukin-8 production [BP] |
| CG_imr90ipsc_promoter_n_PM_14_37_16 |
 |
 |
2 |
0.4 |
2.91E-05 |
ATG3,
SUCLA2,
MECP2,
TCF15 |
double-stranded methylated DNA binding [MF],
respiratory system process [BP],
succinyl-CoA pathway [BP],
Atg8 ligase activity [MF],
neuromuscular process controlling posture [BP] |
| CG_imr90ipsc_promoter_n_PM_16_41_21 |
 |
 |
4 |
0.8 |
4.74E-05 |
BCL2,
SEC31B |
endoplasmic reticulum part [CC],
positive regulation of smooth muscle cell migration [BP] |
| CG_imr90ipsc_promoter_n_PM_14_56_13 |
 |
 |
4 |
0.8 |
1.70E-05 |
FUCA1 |
alpha-L-fucosidase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_71_6 |
 |
 |
1 |
0.2 |
2.40E-05 |
BBC3 |
positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway [BP] |
| CG_imr90ipsc_promoter_n_PM_12_19_10 |
 |
 |
3 |
0.6 |
1.19E-04 |
EZR,
OCA2,
SPRY2 |
arsenite transport [BP],
L-tyrosine transmembrane transporter activity [MF],
tyrosine transport [BP],
ruffle membrane [CC] |
| CG_imr90ipsc_promoter_n_PM_14_77_5 |
 |
 |
2 |
0.4 |
6.19E-05 |
STRA6,
NR5A1,
SULT1B1,
PAPSS1 |
3'-phosphoadenosine 5'-phosphosulfate metabolic process [BP],
adrenal gland development [BP] |
| CG_imr90ipsc_promoter_n_PM_12_314_7 |
 |
 |
1 |
0.2 |
1.67E-04 |
SUV420H1,
TBXA2R |
histone H4-K20 trimethylation [BP],
histone methyltransferase activity (H4-K20 specific) [MF],
thromboxane A2 receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_248_4 |
 |
 |
1 |
0.2 |
1.42E-04 |
MYBPC3,
RGS11,
GNAT2 |
C zone [CC],
extrinsic to internal side of plasma membrane [CC],
heterotrimeric G-protein complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_271_4 |
 |
 |
2 |
0.4 |
3.73E-05 |
AXIN1,
ASAH2,
COMP,
NGB,
AATK,
IL2RA |
cell death [BP],
apoptotic process [BP] |
| CG_imr90ipsc_promoter_n_PM_12_5_28 |
 |
 |
5 |
0.8 |
6.13E-05 |
FGF10 |
positive regulation of urothelial cell proliferation [BP],
mesenchymal-epithelial cell signaling involved in lung development [BP],
secretion by lung epithelial cell involved in lung growth [BP],
mammary gland bud formation [BP],
positive regulation of hair follicle cell proliferation [BP],
urothelial cell proliferation [BP],
mesenchymal cell differentiation involved in lung development [BP],
tear secretion [BP],
semicircular canal fusion [BP],
branch elongation involved in salivary gland morphogenesis [BP],
fibroblast growth factor receptor signaling pathway involved in mammary gland specification [BP],
bronchiole morphogenesis [BP],
lung proximal/distal axis specification [BP],
submandibular salivary gland formation [BP],
positive regulation of white fat cell proliferation [BP],
Harderian gland development [BP] |
| CG_imr90ipsc_promoter_n_PM_12_244_7 |
 |
 |
2 |
0.4 |
1.48E-04 |
AQP7,
PEX19 |
brush border membrane [CC] |
| CG_imr90ipsc_promoter_n_PM_14_95_11 |
 |
 |
4 |
0.6 |
4.95E-05 |
PPAT,
CRYM |
thyroid hormone transport [BP],
thiomorpholine-carboxylate dehydrogenase activity [MF],
amidophosphoribosyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_25_15 |
 |
 |
2 |
0.4 |
5.03E-05 |
SORT1 |
neurotensin receptor activity, non-G-protein coupled [MF],
nerve growth factor receptor activity [MF],
plasma membrane to endosome transport [BP] |
| CG_imr90ipsc_promoter_n_PM_16_3_92 |
 |
 |
6 |
1.0 |
6.38E-05 |
HRAS,
NPC1,
CLN3,
PLA2G1B,
UBXN7,
UBXN1,
SLC4A11 |
negative regulation of macroautophagy [BP],
bicarbonate transmembrane transporter activity [MF],
Cdc48p-Npl4p-Ufd1p AAA ATPase complex [CC],
phosphatidylcholine metabolic process [BP],
positive regulation of miRNA metabolic process [BP] |
| CG_imr90ipsc_promoter_n_PM_14_82_40 |
 |
 |
4 |
0.6 |
5.46E-05 |
ZCRB1,
E2F1,
SF3B1,
RBMX,
MED1,
PRM1,
DHX33,
GTF2E2 |
regulation of transcription from RNA polymerase I promoter [BP],
nucleoplasm [CC],
core promoter binding [MF] |
| CG_imr90ipsc_promoter_n_PM_12_241_17 |
 |
 |
2 |
0.4 |
5.06E-05 |
CBS,
RPL30,
RPL6 |
homocysteine catabolic process [BP],
cysteine biosynthetic process via cystathionine [BP],
cystathionine beta-synthase activity [MF],
cysteine biosynthetic process from serine [BP],
cytosolic large ribosomal subunit [CC],
maternal process involved in female pregnancy [BP] |
| CG_imr90ipsc_promoter_n_PM_14_36_5 |
 |
 |
2 |
0.4 |
5.31E-05 |
DBT,
SLC11A2 |
vanadium ion transmembrane transporter activity [MF],
dihydrolipoyllysine-residue (2-methylpropanoyl)transferase activity [MF],
cobalt ion transmembrane transporter activity [MF],
paraferritin complex [CC],
nickel cation transport [BP],
cadmium ion transmembrane transporter activity [MF],
ferrous iron import [BP],
lead ion transport [BP],
ferrous iron transport [BP],
ferrous iron transmembrane transporter activity [MF],
nickel cation transmembrane transport [BP],
lead ion transmembrane transporter activity [MF],
nickel cation transmembrane transporter activity [MF],
manganese ion transmembrane transport [BP],
vanadium ion transport [BP] |
| CG_imr90ipsc_promoter_n_PM_12_83_8 |
 |
 |
2 |
0.4 |
6.85E-05 |
DHCR24,
DCTD |
dCMP deaminase activity [MF],
delta24-sterol reductase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_16_54_25 |
 |
 |
3 |
0.6 |
9.01E-05 |
CDH17,
WNT10B |
proton-dependent oligopeptide secondary active transmembrane transporter activity [MF],
myoblast cell differentiation involved in skeletal muscle regeneration [BP],
positive regulation of RNA polymerase II transcriptional preinitiation complex assembly [BP],
positive regulation of anagen [BP],
positive regulation of G2/M transition of mitotic cell cycle [BP] |
| CG_imr90ipsc_promoter_n_PM_16_37_19 |
 |
 |
4 |
0.8 |
6.89E-05 |
SCIMP,
GNPTAB |
tetraspanin-enriched microdomain [CC],
uropod membrane [CC],
UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_28_36 |
 |
 |
5 |
0.8 |
5.67E-05 |
KANSL2,
KANSL1,
CAMK2N2,
CAMK2N1,
TRIM63,
USP22,
KANSL3 |
calcium-dependent protein kinase inhibitor activity [MF],
H4 histone acetyltransferase activity [MF],
histone H4-K16 acetylation [BP],
histone acetyltransferase activity (H4-K16 specific) [MF],
histone acetyltransferase activity (H4-K5 specific) [MF],
histone acetyltransferase activity (H4-K8 specific) [MF],
response to interleukin-1 [BP],
histone H4-K8 acetylation [BP],
histone H4-K5 acetylation [BP] |
| CG_imr90ipsc_promoter_n_PM_12_236_12 |
 |
 |
3 |
0.6 |
1.20E-04 |
SOX30,
FOXI3 |
epidermal cell fate specification [BP],
sequence-specific DNA binding RNA polymerase II transcription factor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_115_17 |
 |
 |
2 |
0.4 |
2.49E-04 |
MYH1,
EYA1,
MYH13,
MYH4,
PSD3 |
microfilament motor activity [MF],
motor activity [MF],
neuron differentiation [BP],
response to ionizing radiation [BP],
myosin filament [CC],
muscle myosin complex [CC] |
| CG_imr90ipsc_promoter_n_PM_12_81_6 |
 |
 |
2 |
0.4 |
1.87E-04 |
NTSR2,
CD14 |
G-protein coupled neurotensin receptor activity [MF],
opsonin receptor activity [MF] |
| CG_imr90ipsc_promoter_n_PM_14_68_11 |
 |
 |
3 |
0.6 |
2.47E-05 |
APOA2,
NES |
negative regulation of cholesterol transporter activity [BP],
positive regulation of intermediate filament depolymerization [BP] |
| CG_imr90ipsc_promoter_n_PM_12_387_9 |
 |
 |
3 |
0.6 |
3.41E-05 |
NSUN2,
NACC2 |
negative regulation of G1/S transition of mitotic cell cycle by negative regulation of transcription from RNA polymerase II promoter [BP],
tRNA (cytosine-5-)-methyltransferase activity [MF] |
| CG_imr90ipsc_promoter_n_PM_12_238_10 |
 |
 |
3 |
0.6 |
1.56E-05 |
EIF2AK2 |
evasion or tolerance by virus of host immune response [BP] |